×
About 438 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  150 results

Successful management of acquired hemophilia A onset during pregnancy: A case report.
https://doi.org/10.1111/jog.14938
The Journal of Obstetrics and Gynaecology Research; Nishi A, Muramatsu A et. al.

Jul 16th, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII. Pregnancy could be associated with AHA in younger women. Because of its rarity, the optimal management for pregnancy-related AHA...

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243751
European Journal of Medical Research; Mülling N, Rosery V et. al.

Jul 1st, 2021 - Bleeding is the most common complication of oral anticoagulants, due to inadequate dosing. This report describes the clinical course of a patient who developed severe bleeding under therapy with phenprocoumon, despite an INR in the lower therapeut...

Acquired hemophilia A associated with Epstein-Barr-virus-associated T/natural killer-ce...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078394
Medicine Yamamoto M, Shindo M et. al.

Apr 22nd, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Hematological malignancies, especially lymphoid malignancies, are known to be underlying causes of AHA; however, thus far, there is no re...

A case report of acquired hemophilia following COVID-19 vaccine.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250362
Journal of Thrombosis and Haemostasis : JTH; Radwi M, Farsi S

Mar 31st, 2021 - Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory ...

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 4th, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  4 results

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
https://clinicaltrials.gov/ct2/show/NCT03384277

Dec 12th, 2019 - This is a prospective randomized multi-center controlled pilot trial comparing the regimen of steroid with rituximab and steroid with cyclophosphamide to eradicate anti-factor VIII antibodies in Chinese patients with acquired hemophilia A. Patient...

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT03700229

Nov 23rd, 2018 - This is a prospective, single-arm, open-label clinical trial to evaluate the efficacy and safety the regimen of Bortezomib with rituximab as first-line treatment to eradicate anti-factor VIII antibodies in newly diagnosed acquired hemophilia A. Al...

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT01178294

Oct 23rd, 2017 - This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT00306670

Feb 10th, 2017 - This is a prospective Phase II randomized multi-institutional controlled pilot trial comparing the regimen of single agent rituximab with 6 weeks cytotoxic therapy with oral cyclophosphamide to eradicate or suppress autoimmune anti-factor VIII ant...

see more →

News  14 results

New consensus recommendations on bleeding in acquired hemophilia
https://www.mdedge.com/internalmedicine/article/209872/bleeding-disorders/new-consensus-recommendations-bleeding-acquired?channel=39313
Caleb Rans

Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.

An unusual cause of bruising
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

CHMP recommends change for eptacog alfa
https://www.mdedge.com/hematology-oncology/article/184636/thrombosis/chmp-recommends-change-eptacog-alfa
HT Staff

Oct 20th, 2018 - Photo by Bill Branson Vials of drug The European Medicine’s Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of the marketing authorization for the recombinant factor VIIa product eptacog alfa (N.

see more →